GlassScriptPhysician profile
Kim Lamotte-Malone
NPI 1427008887
$1,377.59
in general payments reported to CMS, 2019-2025
15 companies · $236 in 2025
The $236 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $114 · 2021: $159 · 2022: $89.26 · 2023: $164 · 2024: $346 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $403.96 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Pfizer INC. | $258.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $215.36 | 2019-2025 | Bexsero |
| Sanofi Pasteur INC. | $141.71 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $91.02 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $52.44 | 2024 | Flumist Quadrivalent |
| Seqirus USA INC | $35.20 | 2024 | Flucelvax |
| Cranial Technologies, INC | $33.12 | 2023-2024 | Doc Band |
| Viiv Healthcare Company | $32.49 | 2024 | Dovato |
| Soleno Therapeutics, INC. | $29.50 | 2025 | Vykat Xr |
| Phadia US INC. | $26.33 | 2021-2024 | Immunocap |
| Alexion Pharmaceuticals, INC. | $16.50 | 2019 | |
| Kaleo, INC. | $14.99 | 2021 | |
| Abbvie INC. | $13.40 | 2020 | |
| Aytu Biopharma, INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Lamotte-Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.